Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sigma-Genosys is a prominent supplier of custom synthetic oligonucleotides and peptides, catering to the global life sciences and biotechnology sectors. Founded as Genosys Biotechnologies in 1987, the company was acquired by Sigma-Aldrich in 1998 to bolster its genomics and proteomics service offerings. Today, it operates as a key brand within MilliporeSigma, the life science business of Merck KGaA. The company provides a wide range of products, including DNA and RNA primers, dual-labeled probes for qPCR, and high-purity custom peptides. These tools are fundamental to research in genetic engineering, diagnostics, and drug discovery. Sigma-Genosys is recognized for its high-throughput manufacturing capabilities and stringent quality control processes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sigma-Genosys.